Clinical trial · no report yet · Phase 1/Phase 2
LINKER-MM4
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT05828511 ↗
- Recruiting
- Regeneron Pharmaceuticals
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 16 | |
| YouTube | 7 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab
- Arms
- Phase 1 cohorts · Experimental
- Phase 2 - transplant ineligible cohort · Experimental
- Phase 2 - transplant eligible cohort · Experimental
- Enrollment
- 149 (estimated)
- Primary outcomes
- Incidence of Dose-Limiting Toxicities (DLTs)
- Incidence of Treatment-Emergent Adverse Events (TEAEs)
- Severity of TEAEs
- Incidence of Adverse Events of Special Interest (AESIs)
- Severity of AESIs
- Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
- Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
- Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
- Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
- Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 19, 2023
- Primary completion
- Nov 2, 2035 (estimated)
- Results posted
- No
- Registry record
- NCT05828511 · updated May 13, 2026